Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp

Novartis International AG / Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• 13th International Biotechnology Leadership Camp focuses on potential of new technologies to fundamentally transform biomedical research and the pharmaceutical business
   

Interactive program brings 60 top university students from 18 countries and territories to Novartis headquarters in Switzerland
 

Over the course of three days, students will attend lectures, visit labs and work on a business case exploring opportunities of using digital technologies in healthcare

             
Basel, August 29, 2016 - Novartis today opened the 13th International Biotechnology Leadership Camp (BioCamp). Over the course of three days more than 60 selected students from international universities will discuss and explore with biotechnology and business experts how patients around the world can benefit from innovative technologies.

The digital age has the potential to fundamentally transform biomedical research and the pharmaceutical business. At BioCamp, students and experts will explore these opportunities and discuss ways in which this can benefit patients around the world.

"As a leader in healthcare innovation, Novartis aims to leverage the fundamental transformation that the digital age will bring for biomedical research. This will bring great change to the pharmaceutical industry and is in the best interests of patients and society," said Joseph Jimenez, CEO of Novartis. "Digitalization can foster progress in research and development, make clinical trials more efficient and patient-friendly and allow us to better understand who benefits most from which therapies."

Neuroscience is one of the areas where digital innovation is revolutionizing medical practice. An example highlighted at the event is an innovative movement recording system which aims to quantify a multiple sclerosis (MS) patient's level of disability in a non-invasive, patient-friendly manner. The device measures a patient's movements using a video sensor with machine learning algorithms. Currently under development by Novartis in collaboration with leading MS experts and Microsoft Research, this tool may have the potential to change how neurological dysfunction and disability progression are assessed in MS patients.